Cetuximab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Head and Neck Squamous Cell Carcinoma, Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) ERBITUX is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy [see Dosage and Administration ( 2.3 )] .
  • K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC) ERBITUX is indicated for the treatment of K-Ras wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by an FDA-approved test [see Dosage and Administration ( 2.2 )] : in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinoteca
Product first approved 2004FDA label
JP
  • Treatment of EGFR-expressing, unresectable and advanced/recurrent colorectal carcinomas
Product first approved 2008PMDA
CA
  • Colorectal Cancer ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC)  in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment. The benefits and risks of ERBITUX in combination with FOLFIRI, for first-line treatment in mCRC patients, have been observed only in a subgroup analysis of patients with ECOG performance status of 0 or 1 (see CLINICAL TRIALS).  in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.  as a single...
Product first approved 2005Health Canada
EU
  • Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer: in combination with encorafenib and FOLFOX for the first line treatment; in...
Product first approved 2004EMA

Development in Non-Small Cell Lung Cancer stopped (2012-09) for reasons the sponsor has not stated. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (89)
Head and Neck Squamous Cell Carcinoma
NCT07441681 · NRG Oncology
2026-07-31 – 2040-11-30 · Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
What this study did
NCT07432087 · Yue He, MD
2026-02-01 – 2033-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06589804 · National Cancer Institute (NCI)
2025-03-27 – 2032-12-25 · Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT07509099 · Ji Dongmei
2026-09-15 – 2031-09-30 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06647563 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2024-11-01 – 2030-09-30 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT00956007 · Radiation Therapy Oncology Group
2010-03-31 – 2029-08 · Head and Neck Cancer
What this study did
NCT06998069 · Brown University
2025-08-27 – 2027-06-01 · Head and Neck Neoplasms
What this study did
NCT07435324 · R-Pharm
2024-08-08 – 2026-06-25 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01302834 · Radiation Therapy Oncology Group
2011-06 – 2025-09-04 · Head and Neck Cancer, Precancerous Condition
What this study did
NCT00265941 · Radiation Therapy Oncology Group
2005-11 – 2022-05-20 · Head and Neck Cancer
What this study did
NCT02383966 · Merck KGaA, Darmstadt, Germany
2015-07-31 – 2021-12-20 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT00999700 · Gruppo Oncologico del Nord-Ovest
2009-09 – 2021-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01884623 · Gustave Roussy, Cancer Campus, Grand Paris
2013-11-06 – 2021-10-12 · Head Neck Cancer Squamous Cell Recurrent
What this study did
NCT03349710 · Bristol-Myers Squibb
2017-12-15 – 2019-10-14 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01969877 · Lund University Hospital
2013-11 – 2018-04 · Locally Advanced Head and Neck Cancer
What this study did
NCT00716391 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2008-07-07 – 2017-12 · Head and Neck Cancer
What this study did
NCT01931150 · Memorial Sloan Kettering Cancer Center
2013-08 – 2015-09 · Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
What this study did
NCT01086826 · Associazione Volontari Pazienti Oncologici
2008-03 – 2014-12 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01012258 · Merck KGaA, Darmstadt, Germany
2009-02 – 2014-05 · Squamous Cell Carcinoma of the Head and Neck
What this study did
Metastatic Colorectal Cancer
NCT07389265 · University of Campania Luigi Vanvitelli
2025-10-01 – 2030-10 · Metastatic Colorectal Cancer (mCRC)
What this study did
NCT07913360 · Genfleet Therapeutics (Shanghai) Inc.
2026-11 – 2030-05 · Colorectal Cancer
What this study did
NCT06226857 · City Clinical Oncology Hospital No 1
2024-01-17 – 2027-12-31 · Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
What this study did
NCT04607421 · Pfizer
2020-12-21 – 2027-07-29 · Neoplasms
What this study did
NCT04793958 · Mirati Therapeutics Inc.
2021-06-24 – 2026-10-23 · Advanced Colorectal Cancer, Metastatic Colorectal Cancer
What this study did
NCT03391934 · Cinnagen
2018-01-20 – 2026-02-01 · Metastatic Colorectal Cancer
What this study did
NCT02934529 · Ludwig-Maximilians - University of Munich
2015-03 – 2025-01-30 · Metastatic Colorectal Cancer
What this study did
NCT01910610 · GERCOR - Multidisciplinary Oncology Cooperative Group
2013-10-30 – 2024-12 · Colorectal Cancer Metastatic
What this study did
NCT04262635 · Sun Yat-sen University
2021-09-24 – 2024-08-30 · Colorectal Cancer
What this study did
NCT04835142 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2020-12-31 – 2024-01-26 · Metastatic Colorectal Cancer
What this study did
NCT02484833 · Armando Orlandi
2015-02 – 2020-03 · Antineoplastic Agents
What this study did
NCT00265850 · Alliance for Clinical Trials in Oncology
2005-11 – 2018-01 · Colorectal Cancer
What this study did
NCT01878422 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
2007-11 – 2016-06-11 · Metastatic Colorectal Cancer
What this study did
NCT01030042 · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
2009-09 – 2015-06 · Metastatic Colorectal Cancer
What this study did
NCT00640471 · NCIC Clinical Trials Group
2008-05-12 – 2013-01-10 · Colorectal Cancer
What this study did
NCT00499369 · National Cancer Institute (NCI)
2007-06 – 2012-11 · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT00145314 · The Nordic Colorectal Cancer Biomodulation Group
2005-05 – 2010-08 · Metastatic Colorectal Cancer
What this study did
NCT00252564 · US Oncology Research
2005-09 – 2009-06 · Metastatic Colorectal Cancer
What this study did
NCT00182715 · Velindre NHS Trust
2005-03 – 2009-05 · Colorectal Cancer
What this study did
Other / comorbidity
NCT06997497 · Merck Sharp & Dohme LLC
2025-07-16 – 2030-10-27 · Colon Adenocarcinoma, Rectal Adenocarcinoma
What this study did
NCT06616259 · Meng Qiu
2024-09-26 – 2029-09-30 · Colorectal Cancer (CRC), Capecitabine, Cetuximab
What this study did
NCT05863195 · ECOG-ACRIN Cancer Research Group
2024-04-10 – 2029-06-30 · Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
What this study did
NCT07549399 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-05-20 – 2029-04-30 · Rectal Adenocarcinoma, High-Risk Cancer, MSS
What this study did
Phase 2/3 (11)
Head and Neck Squamous Cell Carcinoma
NCT05063552 · National Cancer Institute (NCI)
2023-03-13 – 2027-12-15 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT01810913 · National Cancer Institute (NCI)
2013-03-22 – 2027-01-01 · Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
Other / comorbidity
NCT05710406 · Alliance for Clinical Trials in Oncology
2023-08-16 – 2034-06-01 · Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
What this study did
NCT02438722 · SWOG Cancer Research Network
2015-05-07 – 2026-04-17 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT02942706 · Ruijin Hospital
2021-11 – 2022-10 · Colorectal Cancer
What this study did
NCT03031444 · Peking University Cancer Hospital & Institute
2016-01 – 2020-12-30 · Colorectal Cancer Stage IV, Metastasis
What this study did
NCT02978313 · Ruijin Hospital
2016-11 – 2019-11 · Colorectal Cancer
What this study did
NCT01211938 · Gustave Roussy, Cancer Campus, Grand Paris
2010-06-15 – 2017-02-25 · Squamous Cell Carcinoma
What this study did
NCT01434394 · Shanghai Jiao Tong University School of Medicine
2011-08 – 2017-02 · Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma, Effects of Chemotherapy
What this study did
NCT00975897 · Medical Research Council
2009-07 – 2012-12 · Colorectal Cancer
What this study did
NCT00509561 · Wales Cancer Trials Unit
2008-02 – 2012-09 · Esophageal Cancer
What this study did
Phase 2 (509)
Head and Neck Squamous Cell Carcinoma
NCT06935188 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2025-04-17 – 2030-12-31 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT07618624 · Sun Yat-sen University
2026-04-20 – 2029-12-31 · Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT05226871 · Pfizer
2022-07-07 – 2029-12-31 · Breast Cancer, Head and Neck Cancer
What this study did
NCT07882888 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-10-16 – 2029-10-16 · Head and Neck Cancer
What this study did
NCT06640725 · Groupe Oncologie Radiotherapie Tete et Cou
2025-01-02 – 2028-12-02 · Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06856213 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2025-06-18 – 2028-10 · Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT06855212 · H. Lee Moffitt Cancer Center and Research Institute
2025-02-26 – 2028-03 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06869473 · Gruppo Oncologico del Nord-Ovest
2025-02-20 – 2028-02-20 · Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
What this study did
NCT07063212 · Memorial Sloan Kettering Cancer Center
2025-07-02 – 2028-01-02 · Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
What this study did
NCT01154920 · M.D. Anderson Cancer Center
2010-07-09 – 2027-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04375384 · Wake Forest University Health Sciences
2020-07-01 – 2027-12 · Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
What this study did
NCT03389477 · Washington University School of Medicine
2018-04-27 – 2027-04-06 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06239220 · Dana-Farber Cancer Institute
2024-02-16 – 2027-03-31 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT06332092 · Fulgent Pharma LLC.
2024-04-10 – 2026-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05993858 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-10-20 – 2026-12-20 · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
What this study did
NCT02270814 · Washington University School of Medicine
2015-02-02 – 2026-09-30 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
What this study did
NCT06508606 · West China Hospital
2024-08-01 – 2026-08-01 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06194656 · Shanghai Institute Of Biological Products
2024-09-27 – 2026-07-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05586100 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2022-10-13 – 2026-04-28 · Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
What this study did
NCT03494322 · University College, London
2018-07-20 – 2026-04-23 · Head and Neck Cancer, Squamous Cell Carcinoma
What this study did
NCT05673577 · Fudan University
2023-03-22 – 2025-12-31 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT05721443 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2022-12-01 – 2025-11-01 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT05271604 · BioAtla, Inc.
2022-12-13 – 2025-09-22 · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03082534 · University of California, San Diego
2017-03-28 – 2025-09-11 · HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05499065 · University Medical Center Groningen
2023-03-01 – 2025-01-10 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06107114 · Xuekui Liu
2023-12-01 – 2024-12-01 · Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
What this study did
NCT03691714 · University of Cincinnati
2018-10-23 – 2024-12-01 · Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
What this study did
NCT05061420 · Sanofi
2021-10-08 – 2024-11-26 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06081582 · First Affiliated Hospital of Zhejiang University
2023-07-06 – 2024-11 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT04278092 · Medical University of Vienna
2020-02-10 – 2024-10-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06046482 · M.D. Anderson Cancer Center
2023-11-28 – 2024-08-26 · Head Neck, Squamous Cell Carcinoma of Head and Neck
What this study did
NCT02573493 · Washington University School of Medicine
2016-04-13 – 2024-07-01 · Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
What this study did
NCT02624128 · National Cancer Institute, Naples
2015-02-23 – 2023-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01588431 · The University of Texas Health Science Center at San Antonio
2011-12 – 2022-10-04 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT03422536 · University of Arizona
2017-12-05 – 2022-04-05 · Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer, Oropharyngeal Cancer, HNSCC, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
What this study did
NCT03769311 · University of Wisconsin, Madison
2019-04-17 – 2022-03-15 · Head and Neck Cancer, Squamous Cell Carcinoma
What this study did
NCT01979211 · University of Cincinnati
2013-10 – 2022-01-19 · Head and Neck Cancer
What this study did
NCT02268695 · Groupe Oncologie Radiotherapie Tete et Cou
2014-10-10 – 2021-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT03646461 · University of California, San Diego
2018-10-17 – 2021-05-13 · Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03254927 · Celldex Therapeutics
2018-03-27 – 2020-12-16 · Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT00904345 · University of Michigan Rogel Cancer Center
2009-04 – 2020-12 · Head and Neck Cancer
What this study did
NCT00736944 · Washington University School of Medicine
2008-12-19 – 2020-07-06 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02057107 · Heath Skinner
2013-07-03 – 2019-12-31 · Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
What this study did
NCT01412229 · UNC Lineberger Comprehensive Cancer Center
2012-02 – 2019-12 · Head and Neck Cancer
What this study did
NCT02124707 · UNC Lineberger Comprehensive Cancer Center
2014-06-16 – 2019-10-01 · Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01437449 · Stanford University
2011-10 – 2019-08 · Head and Neck Cancer
What this study did
NCT00957853 · M.D. Anderson Cancer Center
2011-10-17 – 2018-08-15 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01104922 · David A. Clump, MD, PhD
2007-12-26 – 2018-07-26 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01435252 · University of Zurich
2011-09-19 – 2017-10-25 · Oropharyngeal Cancer, Hypopharyngeal Cancer, Laryngeal Cancer
What this study did
Phase 1/2 (136)
Head and Neck Squamous Cell Carcinoma
NCT07059221 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-07-11 – 2029-03 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT06943820 · Akeso
2025-05-21 – 2028-05 · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
What this study did
NCT05910827 · Hummingbird Bioscience
2024-02-05 – 2027-12 · Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Cancinoma (NPC), Squamous Cell Carcinoma
What this study did
NCT01468896 · National Cancer Institute (NCI)
2011-10-26 – 2027-03-31 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
What this study did
NCT03024489 · Mahidol University
2017-07-19 – 2024-12-31 · Head and Neck Cancer, Locally Advanced
What this study did
NCT04474470 · TyrNovo Ltd.
2020-09-03 – 2024-05-08 · Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
What this study did
NCT03370276 · H. Lee Moffitt Cancer Center and Research Institute
2017-12-20 – 2023-12-23 · Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Paranasal Sinus, Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer, Head and Neck Carcinoma
What this study did
NCT04616196 · Nektar Therapeutics
2020-10-30 – 2023-03-30 · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
What this study did
NCT02643550 · Innate Pharma
2015-12 – 2023-03-28 · Head and Neck Neoplasms
What this study did
NCT04464967 · NKGen Biotech, Inc.
2021-03 – 2023-02 · Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, Esophageal Cancer, Ovarian Cancer, Endometrium Cancer, Bladder Cancer, Pancreatic Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cervical Cancer, Sarcoma
What this study did
NCT02054442 · Radboud University Medical Center
2016-08 – 2022-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03134846 · University Medical Center Groningen
2017-12-16 – 2022-06 · Head and Neck Squamous Cell Carcinoma, Margin Assessment
What this study did
NCT01592721 · The University of Texas Health Science Center at San Antonio
2013-04 – 2022-02-01 · Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT01816984 · University of Chicago
2013-05 – 2020-09 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
What this study did
NCT02507154 · National University Hospital, Singapore
2015-07 – 2019-08 · Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT03109158 · NanoCarrier Co., Ltd.
2017-03-01 – 2019-03-01 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT02143622 · Novartis Pharmaceuticals
2015-03 – 2018-08 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01332266 · Eisai Inc.
2011-09-19 – 2017-09-04 · Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00660218 · State University of New York - Upstate Medical University
2008-03 – 2017-04 · Carcinoma, Squamous Cell
What this study did
NCT01602315 · Novartis Pharmaceuticals
2012-11-12 – 2016-09-16 · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT00704639 · Trans Tasman Radiation Oncology Group
2008-04 – 2015-12 · Head and Neck Cancer
What this study did
NCT00851877 · University of Texas Southwestern Medical Center
2009-03-01 – 2015-08-03 · Head and Neck Cancer
What this study did
NCT01744340 · howard safran
2012-05 – 2015-07 · Head and Neck Cancer, Colon Cancer
What this study did
NCT01283334 · Emory University
2011-01 – 2014-11 · Head and Neck Neoplasms, Cancer of the Head and Neck
What this study did
NCT01252628 · Cascadian Therapeutics Inc.
2010-12 – 2014-01 · Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00570674 · Dana-Farber Cancer Institute
2007-11 – 2013-10 · Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma, Undifferentiated Carcinoma, Adenosquamous Cell Carcinoma
What this study did
NCT00815295 · Duke University
2008-01 – 2013-07 · Squamous Cell Cancer
What this study did
NCT00705016 · Merck KGaA, Darmstadt, Germany
2008-10 – 2013-06 · Squamous Cell Cancer
What this study did
NCT00927147 · Boneca Corporation
2009-06 – 2013-06 · Head and Neck Cancer
What this study did
NCT01015664 · University of Tennessee Cancer Institute
2010-02 – 2012-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00908024 · Bristol-Myers Squibb
2009-10 – 2012-12 · Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
What this study did
NCT00496236 · GenVec
— · Head and Neck Cancer, Head and Neck Neoplasms
What this study did
NCT00714649 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2008-07 – 2011-05 · Head and Neck Cancer
What this study did
NCT01009346 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2009-10 – 2011-03 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT07790510 · Haisco Pharmaceutical Group Co., Ltd.
2026-08-12 – 2030-09-30 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT07683403 · Fudan University
2026-06-30 – 2029-06-30 · Colorectal Cancer (CRC)
What this study did
NCT07912593 · Ensem Therapeutics
2026-10-22 – 2029-04-30 · Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma, Primary Peritoneal Carcinoma
What this study did
NCT06412198 · M.D. Anderson Cancer Center
2024-08-28 – 2029-03-01 · Metastatic Colorectal Cancer, KRAS G12C Mutations
What this study did
NCT04616183 · M.D. Anderson Cancer Center
2020-12-02 – 2028-12-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT07915921 · Genfleet Therapeutics (Shanghai) Inc.
2026-11-15 – 2028-04-30 · CRC
What this study did
NCT04017650 · M.D. Anderson Cancer Center
2019-06-14 – 2027-12-30 · BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT05039177 · Erasca, Inc.
2021-09-20 – 2026-01-26 · Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06776757 · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
2023-12-25 – 2025-12-25 · Metastatic Colorectal Cancer
What this study did
NCT05775900 · Sun Yat-sen University
2023-02-01 – 2025-08-26 · Metastatic Colorectal Cancer
What this study did
NCT04495621 · Menarini Group
2020-07-20 – 2024-02-27 · Metastatic Colorectal Cancer
What this study did
NCT04790448 · Sun Yat-sen University
2020-07-27 – 2021-12-31 · Colorectal Cancer Metastatic
What this study did
NCT02117466 · Amsterdam UMC, location VUmc
2014-04 – 2021-01 · Metastatic Colorectal Cancer
What this study did
Phase 1 (190)
Head and Neck Squamous Cell Carcinoma
NCT07217028 · Vanderbilt-Ingram Cancer Center
2026-04-24 – 2030-09 · SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT07216105 · Fate Therapeutics
2025-11-04 – 2030-01 · Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06806852 · Boehringer Ingelheim
2025-05-14 – 2027-08-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04722523 · Memorial Sloan Kettering Cancer Center
2021-01-20 – 2027-06-20 · Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
What this study did
NCT06005324 · University of Chicago
2023-12-18 – 2026-12 · HPV-Negative Squamous Cell Carcinoma
What this study did
NCT05816785 · University of Wisconsin, Madison
2023-04-18 – 2026-08-08 · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
What this study did
NCT05249426 · Boehringer Ingelheim
2022-04-12 – 2026-06-22 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT05674526 · Allotera Therapeutics
2024-05-21 – 2026-06-01 · Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03498378 · Kathryn Gold
2018-06-06 – 2025-12-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04290546 · Dana-Farber Cancer Institute
2020-07-20 – 2024-12-16 · Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT07435311 · R-Pharm
2020-06-15 – 2024-07-17 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
NCT04091867 · University of Colorado, Denver
2020-01-06 – 2022-10-25 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03524326 · Memorial Sloan Kettering Cancer Center
2018-04-30 – 2022-10-13 · Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
What this study did
NCT04065555 · Presage Biosciences
2020-10-07 – 2022-07-20 · Head and Neck Cancer
What this study did
NCT02764593 · RTOG Foundation, Inc.
2016-06 – 2022-02-21 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT02438995 · Northwell Health
2015-05 – 2021-06 · Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT03319459 · Fate Therapeutics
2018-01-18 – 2020-12-15 · HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
What this study did
NCT02555644 · Eli Lilly and Company
2016-02-24 – 2019-01-14 · Head and Neck Neoplasms
What this study did
NCT01758731 · University of Colorado, Denver
2012-10-22 – 2018-10-31 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02817113 · Orient Europharma Co., Ltd.
2016-06 – 2018-09 · Head and Neck Neoplasms
What this study did
NCT01935921 · National Cancer Institute (NCI)
2013-04-09 – 2018-07-06 · Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT02277197 · James J Lee
2015-08 – 2018-02 · Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
What this study did
NCT01716416 · Washington University School of Medicine
2013-05-31 – 2017-08-31 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01987375 · Eben Rosenthal
2015-11 – 2017-04-19 · Head and Neck Cancer
What this study did
NCT02205398 · Novartis Pharmaceuticals
2014-07-28 – 2017-01-20 · Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
What this study did
NCT02110082 · Bristol-Myers Squibb
2014-04 – 2016-12 · Colorectal Cancer, Head and Neck Cancer
What this study did
NCT01871311 · Georgetown University
2014-05 – 2016-12 · Colorectal Cancer, Head and Neck Cancer
What this study did
NCT02124850 · Celgene
2014-10-28 – 2016-10-31 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00903461 · University of Pittsburgh
2012-04 – 2016-08 · Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
What this study did
NCT02350712 · Daiichi Sankyo
2014-12 – 2016-06 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00882583 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2009-07 – 2016-02 · Head and Neck Cancer
What this study did
NCT01540682 · Abramson Cancer Center at Penn Medicine
2012-02 – 2015-11 · Head and Neck Cancer
What this study did
NCT01451632 · Merrimack Pharmaceuticals
2011-10 – 2014-06 · Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
What this study did
NCT01254617 · National Cancer Institute (NCI)
2011-02-10 – 2014-01-29 · Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Rectal Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Rectal Cancer AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
What this study did
NCT01255800 · University of Colorado, Denver
2011-04 – 2013-12 · Recurrent Head and Neck Cancer
What this study did
NCT01184482 · Georgetown University
2010-06 – 2013-09 · Colorectal Cancer, Lung Cancer, Head and Neck Cancer
What this study did
NCT00397384 · National Cancer Institute (NCI)
2007-01 – 2013-06 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
What this study did
NCT00906360 · National Cancer Institute (NCI)
2008-07 – 2012-09 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
What this study did
NCT01637194 · Fox Chase Cancer Center
2008-11 – 2011-07 · Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Colon Cancer, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Colon Cancer, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Tongue Cancer
What this study did
NCT01360827 · Merck KGaA, Darmstadt, Germany
2010-08 – 2011-04 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00629226 · National Cancer Institute (NCI)
2007-10 – 2010-12 · Head and Neck Cancer
What this study did
NCT01445405 · National Cancer Institute (NCI)
2008-02-05 – 2010-08-27 · Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
What this study did
NCT00622674 · Masonic Cancer Center, University of Minnesota
2005-11 – 2010-02 · Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00402545 · Dana-Farber Cancer Institute
2007-01 – 2009-07 · Head and Neck Neoplasms
What this study did
NCT00291707 · University of Pittsburgh
2006-03 – 2009-01 · Head and Neck Cancer
What this study did
NCT00820417 · Harrison Clinical Research
2004-06 – 2008-05 · Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
What this study did
Metastatic Colorectal Cancer
NCT04929223 · Hoffmann-La Roche
2021-10-22 – 2030-08-31 · Metastatic Colorectal Cancer
What this study did
Phase 4 (8)
Head and Neck Squamous Cell Carcinoma
NCT01553032 · University of Heidelberg Medical Center
2011-06 – 2017-05 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT01564810 · Xu jianmin
2006-09 – 2015-09 · Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms
What this study did
Other / comorbidity
NCT07094893 · Gruppo Oncologico del Nord-Ovest
2026-09-15 – 2030-03 · Colorectal Cancer
What this study did
NCT07302841 · Tianjin Medical University Cancer Institute and Hospital
2026-01-20 – 2028-12-30 · Pancreatic Cancer Non-resectable
What this study did
NCT02015650 · Medical University Innsbruck
2014-04 – 2016-04-19 · Head and Neck Neoplasms
What this study did
NCT00327093 · Hospices Civils de Lyon
2006-05 – 2008-10 · Colorectal Cancer, Neoplasm Metastasis
What this study did
Early phase / not applicable (25)
Head and Neck Squamous Cell Carcinoma
NCT02177838 · Rutgers, The State University of New Jersey
2015-03-25 – 2019-08-22 · Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Tongue Cancer
What this study did
NCT01693159 · National Center for Tumor Diseases, Heidelberg
2011-05 – 2018-11 · Pain
What this study did
NCT01326468 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2011-12-08 – 2016-12 · Head and Neck Cancer
What this study did
NCT00502463 · Austrian South Oncology Group
2007-10-03 – 2014-01-19 · Head and Neck Cancer
What this study did
NCT01790516 · Georgetown University
2012-05 – 2013-06 · Head and Neck Squamous Cell Cancer
What this study did
NCT00891904 · Roswell Park Cancer Institute
2009-04 – 2011-07 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT07874438 · The First Affiliated Hospital with Nanjing Medical University
2026-10-08 – 2029-12-31 · Colorectal Cancer
What this study did
NCT01280643 · Fox Chase Cancer Center
2010-03 – 2014-05 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT06035133 · Tang-Du Hospital
2023-11-10 – 2027-11-10 · Rectal Cancer
What this study did
NCT05424692 · Peking Union Medical College Hospital
2021-09-01 – 2027-09-01 · Colon Cancer, Rectal Cancer, Chemotherapy Effect, PTC, Exon Mutation
What this study did
NCT05963087 · Zhejiang Cancer Hospital
2023-08 – 2026-06 · Advanced Colorectal Cancer
What this study did
NCT05873972 · Fudan University
2023-06-01 – 2024-12-31 · Colorectal Cancer Liver Metastases
What this study did
NCT02324608 · Rutgers, The State University of New Jersey
2015-01-30 – 2023-05-30 · Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
What this study did
NCT03923881 · University Medical Center Groningen
2019-04-11 – 2021-09-30 · Oral Cancer, Lymph Node Metastases
What this study did
NCT01663259 · University of Michigan Rogel Cancer Center
2011-01 – 2019-09 · Squamous Cell Carcinoma of the Oropharynx, HPV
What this study did
NCT01393821 · Mayo Clinic
2012-01-23 – 2018-07-14 · Dermatologic Complications, Malignant Neoplasm, Pain
What this study did
NCT01317433 · Institut Cancerologie de l'Ouest
2010-12-29 – 2016-10-10 · Colorectal Cancer Metastatic, Skin Toxicity
What this study did
NCT02241187 · Memorial Sloan Kettering Cancer Center
2014-09-12 – 2016-09-13 · Pancreatic Cancer
What this study did
NCT01266187 · RWTH Aachen University
2011-07 – 2015-09 · Liver Metastasis
What this study did
NCT01631539 · Universitaire Ziekenhuizen KU Leuven
2012-09 – 2014-12 · Liver Metastases, Colorectal Cancer
What this study did
NCT00498992 · Ingalls Memorial Hospital
started 2006-07 · Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00448838 · University of Miami
2006-05 – 2011-03 · Pancreatic Cancer
What this study did
NCT00084773 · Memorial Sloan Kettering Cancer Center
2004-03 – 2010-03 · Colorectal Cancer
What this study did
NCT00091247 · Alliance for Clinical Trials in Oncology
2004-12 – 2009-07 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00430027 · University of Colorado, Denver
2006-11 – 2008-08 · Esophageal Adenocarcinoma
What this study did
Used as active comparator (52)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (23)
Head and Neck Squamous Cell Carcinoma
NCT05751512 · Lepu Biopharma Co., Ltd.
2023-04-04 – 2027-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02358031 · Merck Sharp & Dohme LLC
2015-03-19 – 2023-07-19 · Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
What this study did
NCT02252042 · Merck Sharp & Dohme LLC
2014-11-17 – 2022-08-15 · Head and Neck Squamous Cell Cancer
What this study did
NCT02105636 · Bristol-Myers Squibb
2014-05-29 – 2021-09-10 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02551159 · AstraZeneca
2015-10-15 – 2021-05-21 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03342352 · Incyte Corporation
2017-12-15 – 2018-04-20 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer
2022-10-24 – 2030-07-03 · Colorectal Neoplasms
What this study did
NCT07595276 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2026-05-27 – 2030-06-01 · Colorectal Cancer
What this study did
NCT06008119 · Shanghai Kechow Pharma, Inc.
2023-10-25 – 2026-12-24 · Colorectal Cancer Metastatic
What this study did
NCT04776655 · Azienda USL Reggio Emilia - IRCCS
2021-04-30 – 2026-12 · Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation
What this study did
NCT01001377 · Amgen
2010-02-02 – 2017-03-07 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT06750094 · Janssen Research & Development, LLC
2024-12-12 – 2029-04-13 · Colorectal Neoplasms
What this study did
NCT07768189 · Corbus Pharmaceuticals Inc.
2026-09-29 – 2029-03 · Oropharyngeal Carcinoma (OPC)
What this study did
NCT05239741 · Merck Sharp & Dohme LLC
2022-04-02 – 2028-09-19 · Colorectal Neoplasms
What this study did
Phase 2/3 (1)
Head and Neck Squamous Cell Carcinoma
NCT03258554 · National Cancer Institute (NCI)
2018-04-03 – 2025-09-04 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma of Unknown Primary, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
Phase 2 (19)
Head and Neck Squamous Cell Carcinoma
NCT04282109 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2020-06-03 – 2024-03-21 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT02707588 · Groupe Oncologie Radiotherapie Tete et Cou
2016-05-18 – 2022-10-17 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02052960 · Glycotope GmbH
2014-02 – 2017-10-04 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT01577173 · Genentech, Inc.
2012-07 – 2015-06 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT07070713 · Fujian Cancer Hospital
2025-07-30 – 2028-08-30 · Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
What this study did
NCT03186326 · Federation Francophone de Cancerologie Digestive
2018-04-24 – 2025-03-01 · Metastatic Colorectal Cancer, MSI
What this study did
NCT04466254 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2020-12-07 – 2022-03-30 · Metastatic Colorectal Cancer
What this study did
NCT03688230 · SFJ Pharmaceuticals X, LTD.
2019-04 – 2021-08 · Metastatic Colorectal Cancer
What this study did
NCT01925274 · Pfizer
2013-11-15 – 2016-04-06 · Metastatic Colorectal Cancer
What this study did
NCT01152437 · Boehringer Ingelheim
2010-06 – 2012-03 · Colorectal Neoplasms
What this study did
Other / comorbidity
NCT07042295 · National Cancer Institute (NCI)
2026-03-23 – 2029-02-28 · Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
What this study did
NCT06306846 · Jiang Feng
2023-10-01 – 2026-12-31 · Head and Neck Squamous Carcinoma
What this study did
NCT01836653 · EPS Corporation
2013-05 – 2017-03 · Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
What this study did
NCT01609231 · Merck Sharp & Dohme LLC
2012-07-06 – 2014-12-09 · Rectal Neoplasms
What this study did
NCT00514943 · Boehringer Ingelheim
2007-08 – 2013-07 · Head and Neck Neoplasms, Carcinoma, Squamous Cell
What this study did
NCT00551213 · Merck Sharp & Dohme LLC
2007-11-21 – 2009-06-04 · Colorectal Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03693612 · GlaxoSmithKline
2018-11-26 – 2021-09-16 · Neoplasms
What this study did
Phase 1 (7)
Head and Neck Squamous Cell Carcinoma
NCT01046266 · Hoffmann-La Roche
2009-11 – 2012-06 · Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT03356158 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2017-11-15 – 2018-11-30 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT07813468 · HC Biopharma Inc.
2026-09-12 – 2027-06-30 · Cetuximab, Bioequivalence, Healthy Volunteers, Pharmacokinetics
What this study did
NCT06980454 · Shanghai Henlius Biotech
2025-06-04 – 2025-12-31 · Cancer, mCRC
What this study did
NCT03491709 · Dragonboat Biopharmaceutical Company Limited
2018-07-01 – 2019-09-18 · Colorectal Cancer
What this study did
NCT03881787 · Dragonboat Biopharmaceutical Company Limited
2017-04-19 – 2019-08-19 · Healthy Volunteers
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01834014 · EPS Corporation
2013-05 – 2017-03 · Liver Metastasis, Colorectal Cancer
What this study did
Appears in other studies (20)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Head and Neck Squamous Cell Carcinoma
NCT04966481 · Washington University School of Medicine
2022-04-06 – 2029-02-28 · HPV-unrelated Head and Neck Squamous Cell Carcinoma
What this study did
NCT06064877 · AVEO Pharmaceuticals, Inc.
2024-01-11 – 2027-11 · Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT04590963 · AstraZeneca
2020-10-02 – 2026-09-24 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT05930938 · Groupe Oncologie Radiotherapie Tete et Cou
2023-12-12 – 2024-09-30 · Squamous Cell Carcinoma of the Head and Neck
What this study did
Other / comorbidity
NCT07004413 · Charite University, Berlin, Germany
2026-10-01 – 2031-10-01 · Colorectal Cancer Metastatic
What this study did
Phase 2 (11)
Head and Neck Squamous Cell Carcinoma
NCT04883281 · University of Texas Southwestern Medical Center
2022-02-23 – 2026-03-11 · Head and Neck Cancer
What this study did
NCT02499120 · Pfizer
2015-09-10 – 2022-09-07 · Squamous Cell Carcinoma of the Head and Neck (SCCHN)
What this study did
NCT01040832 · EMD Serono
2009-12 – 2012-01 · Squamous Cell Carcinoma of the Head and Neck Cancer
What this study did
Metastatic Colorectal Cancer
NCT06967155 · Blokhin's Russian Cancer Research Center
2025-03-01 – 2028-06-10 · Neoplasms
What this study did
NCT05291156 · University of Campania Luigi Vanvitelli
2022-07-21 – 2025-07-01 · Metastatic Colorectal Cancer
What this study did
NCT02292758 · Academic and Community Cancer Research United
2014-12-12 – 2019-09-27 · Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT00614393 · Merck Sharp & Dohme LLC
2007-12-24 – 2012-03-07 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT06590259 · Shanghai 6th People's Hospital
2024-03-12 – 2027-12 · Colorectal Cancer Liver Metastasis
What this study did
NCT03164655 · UNICANCER
2018-07-25 – 2021-11-15 · Colorectal Cancer Metastatic
What this study did
NCT02633800 · Daiichi Sankyo
2015-12-22 – 2018-02-21 · Head and Neck Neoplasms
What this study did
NCT00203931 · University of Chicago
2005-03 – 2009-11 · Non-small Cell Lung Cancer
What this study did
Phase 1/2 (3)
Metastatic Colorectal Cancer
NCT01075048 · Daiichi Sankyo
2010-01-26 – 2015-02-20 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT04585035 · InventisBio Co., Ltd
2020-10-02 – 2025-12 · Solid Tumor, Adult, NSCLC, CRC
What this study did
NCT02845856 · Fuda Cancer Hospital, Guangzhou
2016-07-01 – 2019-07-01 · Recurrent Non-small Cell Lung Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT03360734 · Glycotope GmbH
2017-11-02 – 2020-09-29 · Solid Tumor, Adult
What this study did

Competitive landscape

This mechanism is crowded: 41 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cetuximab: this drugApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Erlotinib
Approved(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
Gefitinib
Approved(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
Lazertinib
Approved(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)
Approved(overall)
Small moleculeEGFR
Reliable signal(overall)
No reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Sunvozertinib (Zegfrovy)
Approved(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Almonertinib
Phase 3(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Andamertinib
Phase 3(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Asandeutertinib
Phase 3(overall)
Small moleculeEGFR
Weak signal(overall)
No reviewed efficacy summary in this indication
Becotatug
Phase 3(overall)
Monoclonal antibodyEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
Befotertinib
Phase 3(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
FHND9041
Phase 3(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Furmonertinib
Phase 3(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Icotinib
Phase 3(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
Limertinib
Phase 3(overall)
Small moleculeEGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR)
Reliable signal(overall)
No reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
Pruvonertinib
Phase 3(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Rezivertinib
Phase 3(overall)
Small moleculeEGFR
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rilertinib (SH-1028)
Phase 3(overall)
Small moleculeEGFR
Reliable signal(overall)
No reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Zipalertinib
Phase 3(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pimurutamab
Phase 2/3(overall)
Monoclonal antibodyEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Zorifertinib
Phase 2/3(overall)
Small moleculeEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
BEBT-109
Phase 2(overall)
Small moleculeEGFR
Weak signal(overall)
No reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS111
Phase 2(overall)
Small moleculeEGFR
Weak signal(overall)
No reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
Sutetinib
Phase 2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
ANS02
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
BBT-207
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
BH-30643
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
BPI-361175
Phase 1/2(overall)
Small moleculeEGFR
Weak signal(overall)
No reviewed efficacy summary in this indication
Dositinib Mesylate
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
DZD6008
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
H002
Phase 1/2(overall)
Small moleculeEGFR
Weak signal(overall)
No reviewed efficacy summary in this indication
JIN-A02
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
PH009-1
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
Silevertinib
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
STX-241
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
VRN110755
Phase 1/2(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
ALX2004
Phase 1(overall)
Antibody–drug conjugateEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
AST2303
Phase 1(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
EPI-326
Phase 1(overall)
Multispecific antibodyEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
HLX42
Phase 1(overall)
Antibody–drug conjugateEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
HSK40118
Phase 1(overall)
Small moleculeEGFR
not yet graded(overall)
No reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(166 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cetuximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (14)
December 2026 (14)
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06943820 · CT.gov ↗
What to watch
Phase 2Advanced Malignant TumourRecruiting
Est. primary completion 2026-12 · NCT06915142 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT04375384 · CT.gov ↗
What to watch
Phase 2Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVAActive not recruiting
Est. primary completion 2026-12 · NCT01025089 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06998069 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2026-12-15 · NCT06797336 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, BRAF V600E Mutation PositiveRecruiting
Est. primary completion 2026-12-30 · NCT05706779 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-30 · NCT06321081 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer MetastaticRecruiting
Est. primary completion 2026-12-31 · NCT06763029 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT07257653 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT05959356 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06239220 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06226857 · CT.gov ↗
What to watch
2027 (53)
January 2027 (5)
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-01-01 · NCT06179160 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-01-02 · NCT06715124 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-01-19 · NCT05584670 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma …Recruiting
Est. primary completion 2027-01-30 · NCT06102902 · CT.gov ↗
What to watch
Phase 2Unresectable Metastatic Rectal Cancer, CAPOX, Combination of RadioimmunotherapyNot yet recruiting
Est. primary completion 2027-01-30 · NCT07059949 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Advanced Refractory Solid TumorsNot yet recruiting
Est. primary completion 2027-02-10 · NCT07327411 · CT.gov ↗
What to watch
March 2027 (3)
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07059221 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-03-27 · NCT06818812 · CT.gov ↗
What to watch
Phase 2LA HNSCCRecruiting
Est. primary completion 2027-03-31 · NCT06978829 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch
Phase 1/2KRAS P.G12CRecruiting
Est. primary completion 2027-04 · NCT05410145 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-04-01 · NCT06227377 · CT.gov ↗
What to watch
May 2027 (5)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-05-01 · NCT06411600 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Oral Cavity Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT06448026 · CT.gov ↗
What to watch
Phase 2Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2027-05-20 · NCT07000305 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-05-31 · NCT07559760 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerEnrolling by invitation
Est. primary completion 2027-05-31 · NCT06959589 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRASRecruiting
Est. primary completion 2027-06 · NCT07644559 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-06 · NCT07659795 · CT.gov ↗
What to watch
Phase 1CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04485013 · CT.gov ↗
What to watch
Phase 1Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-06-05 · NCT06912087 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-20 · NCT04722523 · CT.gov ↗
What to watch
Phase 4Pancreatic Cancer Non-resectableNot yet recruiting
Est. primary completion 2027-06-20 · NCT07302841 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07543471 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)Recruiting
Est. primary completion 2027-07 · NCT07259590 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07079410 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2027-07-01 · NCT06428500 · CT.gov ↗
What to watch
August 2027 (4)
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-08 · NCT06917079 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-20 · NCT06869473 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2027-08-31 · NCT05355701 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06806852 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2027-09 · NCT07198841 · CT.gov ↗
What to watch
Phase 1Colon Cancer, Colorectal CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT05722327 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-09-30 · NCT07474727 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-10-02 · NCT06640725 · CT.gov ↗
What to watch
Phase 1Advanced Malignant TumorsRecruiting
Est. primary completion 2027-10-15 · NCT06764771 · CT.gov ↗
What to watch
Phase 2Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic CancerNot yet recruiting
Est. primary completion 2027-10-30 · NCT07446270 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS MutationRecruiting
Est. primary completion 2027-11 · NCT07678593 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-10 · NCT06978400 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (13)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 3HNSCCActive not recruiting
Est. primary completion 2027-12 · NCT02999087 · CT.gov ↗
What to watch
Phase 1RhabdomyosarcomaRecruiting
Est. primary completion 2027-12-01 · NCT06865664 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT05910827 · CT.gov ↗
What to watch
Phase 2/3Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-15 · NCT05063552 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT04017650 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07059338 · CT.gov ↗
What to watch
Phase 1Unresectable Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06540261 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2027-12-31 · NCT04449874 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer MetastaticRecruiting
Est. primary completion 2027-12-31 · NCT07012954 · CT.gov ↗
What to watch
Phase 2Rectal Cancer Stage IIIActive not recruiting
Est. primary completion 2027-12-31 · NCT03391843 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT07618624 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT01154920 · CT.gov ↗
What to watch
2028 (44)
January 2028 (5)
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01 · NCT07216105 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01 · NCT06725368 · CT.gov ↗
What to watch
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01-02 · NCT07063212 · CT.gov ↗
What to watch
Phase 1Relapsed Solid Tumor Malignancies, Refractory Solid Tumor MalignanciesRecruiting
Est. primary completion 2028-01-15 · NCT07672483 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-02-16 · NCT07415031 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2028-03 · NCT06586515 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT06855212 · CT.gov ↗
What to watch
Phase 4Colorectal CancerNot yet recruiting
Est. primary completion 2028-03 · NCT07094893 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-03-28 · NCT05985954 · CT.gov ↗
What to watch
April 2028 (5)
Phase 1Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-04 · NCT07349537 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-04 · NCT07458347 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruitingDiscontinued in this indication
Est. primary completion 2028-04 · NCT07551778 · CT.gov ↗
What to watch
Phase 2Locally Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07503639 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07915921 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruitingDiscontinued in this indication
Est. primary completion 2028-05-31 · NCT07463677 · CT.gov ↗
What to watch
June 2028 (5)
Phase 1/2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-06 · NCT05786924 · CT.gov ↗
What to watch
Phase 2RAS Wild Type mCRCNot yet recruiting
Est. primary completion 2028-06-01 · NCT07490119 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07683403 · CT.gov ↗
What to watch
Phase 3Carcinoma, Squamous CellRecruiting
Est. primary completion 2028-06-30 · NCT04892173 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07874438 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Colorectal Cancer (CRC)Recruiting
Est. primary completion 2028-07-01 · NCT07896681 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-07-31 · NCT07722754 · CT.gov ↗
What to watch
September 2028 (5)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-09-01 · NCT06440902 · CT.gov ↗
What to watch
Phase 2Chordoma, Metastatic Chordoma, Unresectable ChordomaActive not recruiting
Est. primary completion 2028-09-01 · NCT05041127 · CT.gov ↗
What to watch
Phase 1RAS Mutation, Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2028-09-30 · NCT07746141 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
Phase 3Colorectal Cancer (CRC), Capecitabine, CetuximabNot yet recruiting
Est. primary completion 2028-09-30 · NCT06616259 · CT.gov ↗
What to watch
October 2028 (6)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10 · NCT06856213 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10-16 · NCT07882888 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-10-18 · NCT07300150 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-10-30 · NCT07912593 · CT.gov ↗
What to watch
November 2028 (4)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2028-11 · NCT06973564 · CT.gov ↗
What to watch
Phase 2Colorectal NeoplasmsNot yet recruiting
Est. primary completion 2028-11 · NCT07814417 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-11 · NCT07913360 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, Peritoneal Metastases, CarcinomatosisRecruiting
Est. primary completion 2028-11-15 · NCT07411599 · CT.gov ↗
What to watch
December 2028 (6)
Phase 1/2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBMRecruiting
Est. primary completion 2028-12 · NCT02861898 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01Recruiting
Est. primary completion 2028-12 · NCT07581912 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-12-31 · NCT05382559 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04616183 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT06935188 · CT.gov ↗
What to watch
2029 (30)
January 2029 (2)
Phase 3Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck TumorRecruiting
Est. primary completion 2029-01 · NCT06706401 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer, Minimal Residual DiseaseActive not recruiting
Est. primary completion 2029-01-18 · NCT06358430 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Advanced Colorectal CancerRecruiting
Est. primary completion 2029-02-01 · NCT06369259 · CT.gov ↗
What to watch
March 2029 (2)
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-03-01 · NCT06412198 · CT.gov ↗
What to watch
Phase 3Colon Adenocarcinoma, Rectal AdenocarcinomaRecruiting
Est. primary completion 2029-03-28 · NCT06997497 · CT.gov ↗
What to watch
April 2029 (4)
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-04 · NCT07217028 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-04-01 · NCT06207656 · CT.gov ↗
What to watch
Phase 1Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma …Recruiting
Est. primary completion 2029-04-14 · NCT07318805 · CT.gov ↗
What to watch
Phase 3Rectal Adenocarcinoma, High-Risk Cancer, MSSRecruiting
Est. primary completion 2029-04-30 · NCT07549399 · CT.gov ↗
What to watch
May 2029 (5)
Phase 1Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2029-05 · NCT06835569 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-05-01 · NCT06241456 · CT.gov ↗
What to watch
Phase 1Solid Tumors, Advanced Solid Tumors, Metastatic Solid TumorsRecruiting
Est. primary completion 2029-05-03 · NCT05836324 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer Metastatic to LiverNot yet recruiting
Est. primary completion 2029-05-27 · NCT07863869 · CT.gov ↗
What to watch
June 2029 (3)
Phase 1/2Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2029-06-11 · NCT07468071 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2029-06-30 · NCT06720987 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8 …Recruiting
Est. primary completion 2029-06-30 · NCT05863195 · CT.gov ↗
What to watch
July 2029 (2)
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-07-27 · NCT07535112 · CT.gov ↗
What to watch
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
September 2029 (2)
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-09-30 · NCT07790510 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT06647563 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2029-10 · NCT04587128 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma …Recruiting
Est. primary completion 2029-10-01 · NCT05956821 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2029-11-01 · NCT07621497 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1/2Advanced Solid MalignanciesNot yet recruiting
Est. primary completion 2029-12-29 · NCT07939815 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2029-12-31 · NCT07030959 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib, Cetuximab N01Recruiting
Est. primary completion 2029-12-31 · NCT07789210 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (12)
January 2030 (1)
Phase 1Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2030-01 · NCT06607185 · CT.gov ↗
What to watch
February 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-02-25 · NCT05067283 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-09 · NCT07183865 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-10 · NCT06928584 · CT.gov ↗
What to watch
Phase 1Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal AdenocarcinomaNot yet recruiting
Est. primary completion 2030-03-22 · NCT07897721 · CT.gov ↗
What to watch
July 2030 (2)
Phase 2Betel-nut-associated Oral CarcinomaNot yet recruiting
Est. primary completion 2030-07 · NCT07733466 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-07-30 · NCT06418724 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2030-08-31 · NCT04929223 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Metastatic Colorectal CancerRecruiting
Est. primary completion 2030-10 · NCT07389265 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1Malignant NeoplasmRecruiting
Est. primary completion 2030-12-01 · NCT07247110 · CT.gov ↗
What to watch
Phase 2Colorectal Liver Metastasis (CRLM)Recruiting
Est. primary completion 2030-12-31 · NCT06988852 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07432087 · CT.gov ↗
What to watch
2031 (5)
March 2031 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2031-03-30 · NCT07381764 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney TransplantNot yet recruiting
Est. primary completion 2031-04-30 · NCT07715734 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-09-30 · NCT07509099 · CT.gov ↗
What to watch
December 2031 (2)
Phase 1KRAS Mutant Solid TumorsRecruiting
Est. primary completion 2031-12-03 · NCT07204340 · CT.gov ↗
What to watch
Phase 2Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-12-16 · NCT02128906 · CT.gov ↗
What to watch
2032 (4)
March 2032 (1)
Phase 1Solid TumorsNot yet recruiting
Est. primary completion 2032-03-30 · NCT07905924 · CT.gov ↗
What to watch
April 2032 (1)
Phase 2Neoplasm MalignantRecruiting
Est. primary completion 2032-04-09 · NCT07209111 · CT.gov ↗
What to watch
November 2032 (1)
Phase 1Advanced or Metastatic Solid Tumors With KRAS G12D MutationNot yet recruiting
Est. primary completion 2032-11-05 · NCT07926334 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-12-25 · NCT06589804 · CT.gov ↗
What to watch
2034 (1)
June 2034 (1)
Phase 2/3Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8 …Active not recruiting
Est. primary completion 2034-06-01 · NCT05710406 · CT.gov ↗
What to watch
2035 (2)
May 2035 (1)
Phase 2Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor …Recruiting
Est. primary completion 2035-05 · NCT02800486 · CT.gov ↗
What to watch
November 2035 (1)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2035-11-30 · NCT07441681 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗